Developing tau-targeting medicines for Alzheimer’s disease and related disorders
Abnormal tau protein forms clumps that contribute to nerve-cell damage in Alzheimer’s disease and related brain disorders. Progressive dementia disrupts memory, thinking and daily activities, eventually causing loss of independence and dependence on full-time care.
Glyx Therapeutics is developing an oral small-molecule medicine targeting tau protein in the brain. Its preclinical programme aims to slow disease progression in Alzheimer’s disease and rare tauopathies.
What stands out about Glyx Therapeutics
Signed an exclusive licence with SATT Nord in 2026 covering a patent and know-how for its therapeutic programme.
Source ↗Established in vivo proof of concept for its lead compound in the rTg4510 tauopathy mouse model.
Source ↗Spun out of research at UPJV’s LG2A and UPEC’s Gly-CRRET laboratories to develop oral treatments for tauopathies.
Source ↗Co-founded by Anne Wadouachi, an UPJV professor whose sugar-chemistry research underpins the therapeutic programme.
Source ↗Led by co-founder Fabrice Beauchêne, who founded clinical research organisation POPSI CUBE in 2004.
Source ↗Awarded a €90,000 French Tech Emergence Deeptech grant with support from Bpifrance, Hauts-de-France and Amiens Métropole.
Source ↗Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.